389 related articles for article (PubMed ID: 31362654)
21. Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia.
Thuret I; Ruggeri A; Angelucci E; Chabannon C
Stem Cells Transl Med; 2022 Apr; 11(4):407-414. PubMed ID: 35267028
[TBL] [Abstract][Full Text] [Related]
22. Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches.
Sripichai O; Fucharoen S
Expert Rev Hematol; 2016 Dec; 9(12):1129-1137. PubMed ID: 27801605
[TBL] [Abstract][Full Text] [Related]
23. Recent perspectives of pediatric β-thalassemia.
An Q; Fan C; Xu S
Minerva Pediatr (Torino); 2022 Jun; 74(3):365-372. PubMed ID: 29479942
[TBL] [Abstract][Full Text] [Related]
24. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
25. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
26. Towards more successful gene therapy clinical trials for β-thalassemia.
Drakopoulou E; Papanikolaou E; Georgomanoli M; Anagnou NP
Curr Mol Med; 2013 Sep; 13(8):1314-30. PubMed ID: 23865429
[TBL] [Abstract][Full Text] [Related]
27. Alpha and beta thalassemia.
Muncie HL; Campbell J
Am Fam Physician; 2009 Aug; 80(4):339-44. PubMed ID: 19678601
[TBL] [Abstract][Full Text] [Related]
28. Gene therapies for transfusion dependent β-thalassemia: Current status and critical criteria for success.
Soni S
Am J Hematol; 2020 Sep; 95(9):1099-1112. PubMed ID: 32562290
[TBL] [Abstract][Full Text] [Related]
29. Molecular genetics of β-thalassemia: A narrative review.
Jaing TH; Chang TY; Chen SH; Lin CW; Wen YC; Chiu CC
Medicine (Baltimore); 2021 Nov; 100(45):e27522. PubMed ID: 34766559
[TBL] [Abstract][Full Text] [Related]
30. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong AC; Rivella S
Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
[TBL] [Abstract][Full Text] [Related]
31. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
[TBL] [Abstract][Full Text] [Related]
32. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
Magrin E; Miccio A; Cavazzana M
Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
[TBL] [Abstract][Full Text] [Related]
33. Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.
Fornari TA; Lanaro C; Albuquerque DM; Ferreira R; Costa FF
Exp Biol Med (Maywood); 2017 Feb; 242(3):267-274. PubMed ID: 27591578
[TBL] [Abstract][Full Text] [Related]
34. Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.
Eckrich MJ; Frangoul H
Semin Hematol; 2023 Jan; 60(1):3-9. PubMed ID: 37080708
[TBL] [Abstract][Full Text] [Related]
35. Inducing indel mutation in the SOX6 gene by zinc finger nuclease for gamma reactivation: An approach towards gene therapy of beta thalassemia.
Modares Sadeghi M; Shariati L; Hejazi Z; Shahbazi M; Tabatabaiefar MA; Khanahmad H
J Cell Biochem; 2018 Mar; 119(3):2512-2519. PubMed ID: 28941328
[TBL] [Abstract][Full Text] [Related]
36. [Current management of thalassemia intermedia].
Thuret I
Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
[TBL] [Abstract][Full Text] [Related]
37. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
[TBL] [Abstract][Full Text] [Related]
38. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy.
Srivastava A; Shaji RV
Haematologica; 2017 Feb; 102(2):214-223. PubMed ID: 27909215
[TBL] [Abstract][Full Text] [Related]
39. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.
Marktel S; Scaramuzza S; Cicalese MP; Giglio F; Galimberti S; Lidonnici MR; Calbi V; Assanelli A; Bernardo ME; Rossi C; Calabria A; Milani R; Gattillo S; Benedicenti F; Spinozzi G; Aprile A; Bergami A; Casiraghi M; Consiglieri G; Masera N; D'Angelo E; Mirra N; Origa R; Tartaglione I; Perrotta S; Winter R; Coppola M; Viarengo G; Santoleri L; Graziadei G; Gabaldo M; Valsecchi MG; Montini E; Naldini L; Cappellini MD; Ciceri F; Aiuti A; Ferrari G
Nat Med; 2019 Feb; 25(2):234-241. PubMed ID: 30664781
[TBL] [Abstract][Full Text] [Related]
40. Molecular basis of β thalassemia and potential therapeutic targets.
Thein SL
Blood Cells Mol Dis; 2018 May; 70():54-65. PubMed ID: 28651846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
